After a slow start to 2025, biopharma rebounded strongly in the second half, with DealForma data highlighting a buoyant Q4 marked by renewed momentum in M&A, PIPEs, and follow-on financings, raising optimism for 2026. Read it here
After a slow start to 2025, biopharma rebounded strongly in the second half, with DealForma data highlighting a buoyant Q4 marked by renewed momentum in M&A, PIPEs, and follow-on financings, raising optimism for 2026. Read it here
DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.
Database
Company
Comparisons
Website Design by Once Interactive
